That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

The results also make MariTide the first obesity treatment with monthly or less frequent dosing to show effective weight loss in a phase 2 study, according to the company. Despite that assessment ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

MariTide demonstrated robust weight loss at 52 weeks without a weight loss plateau, significant improvements in cardiometabolic parameters, and is the first obesity treatment with monthly or less ...

Amgen's weight loss drug only needs to be taken once a month The top GLP-1 treatments on the market today require weekly injections. But MariTide, which is Amgen's GLP-1 drug, only needs to be ...

Skovronsky said the race to create the next great drug is not just about weight loss anymore, something more investors and analysts are starting to say. Take Amgen's experimental drug MariTide ...

MariTide Phase 3 studies to begin in first half ... placed a hold on an early-stage trial of a different experimental weight-loss drug. The company's shares, which have gained more than 11% ...

Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...